Inovio Pharmaceuticals (INO) : Traders are bullish on Inovio Pharmaceuticals (INO) as it has outperformed the S&P 500 by a wide margin of 2.23% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 8.29%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 8.21% in the last 1 week, and is up 5.67% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 7.98% and the 50-Day Moving Average is 1.11%. Inovio Pharmaceuticals, Inc. has dropped 5.73% during the last 3-month period . Year-to-Date the stock performance stands at 47.02%.
Inovio Pharmaceuticals (NASDAQ:INO): stock turned positive on Friday. Though the stock opened at $9.54, the bulls momentum made the stock top out at $9.93 level for the day. The stock recorded a low of $9.43 and closed the trading day at $9.88, in the green by 2.70%. The total traded volume for the day was 1,487,852. The stock had closed at $9.62 in the previous days trading.
Inovio Pharmaceuticals, Inc. (Inovio) is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. As of December 31, 2014, Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, influenza and Ebola. With its immunotherapy platform consisting of SynCon products, as well as its CELLECTRA electroporation delivery technology, Inovio has developed a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovios immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.